Thetis Pharmaceuticals LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD) ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

A person’s risk of developing bowel cancer may depend on different factors, such as how long they have had inflammatory bowel ...